Keros Therapeutics (KROS) Net Income towards Common Stockholders (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Net Income towards Common Stockholders came in at -$23.5 million in Q4 2025, up 49.03% YoY from -$15.7 million in Q4 2024, and down 222.27% on a QoQ basis from -$7.3 million in Q3 2025.
Keros Therapeutics (KROS) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$23.5 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 49.03% year-over-year to -$23.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $87.0 million (up 146.44% YoY) and the FY2025 annual result came in at $87.0 million, up 146.44% from the prior year.
- Net Income towards Common Stockholders eased to -$23.5 million in Q4 2025, from -$7.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $148.5 million in Q1 2025 to a low of -$53.0 million in Q3 2024.
- A 5-year average of -$20.8 million and a median of -$28.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 328.21% — and 2025, when it jumped 444.32%.
- Tracing KROS's Net Income towards Common Stockholders over 5 years: stood at -$6.9 million in 2021, then sank by 328.21% to -$29.7 million in 2022, then sank by 35.42% to -$40.2 million in 2023, then slipped by 14.37% to -$46.0 million in 2024, then soared by 49.03% to -$23.5 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$23.5 million (Q4 2025), -$7.3 million (Q3 2025), and -$30.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | -28.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.71 Mn |
| Dec 31, 2025 | -23.46 Mn |
| Sep 30, 2025 | -7.28 Mn |
| Jun 30, 2025 | -30.70 Mn |
| Mar 31, 2025 | 148.45 Mn |
| Dec 31, 2024 | -46.03 Mn |
| Sep 30, 2024 | -52.96 Mn |
| Jun 30, 2024 | -45.26 Mn |
| Mar 31, 2024 | -43.11 Mn |
| Dec 31, 2023 | -40.24 Mn |
| Sep 30, 2023 | -39.44 Mn |
| Jun 30, 2023 | -37.51 Mn |
| Mar 31, 2023 | -35.80 Mn |
| Dec 31, 2022 | -29.72 Mn |
| Sep 30, 2022 | -23.51 Mn |
| Jun 30, 2022 | -27.27 Mn |
| Mar 31, 2022 | -24.19 Mn |
| Dec 31, 2021 | -6.94 Mn |
| Sep 30, 2021 | -20.30 Mn |
| Jun 30, 2021 | -15.62 Mn |